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Abstract
Background: Despite advances in HIV treatment, bacterial pneumonia continues to cause considerable morbidity and
mortality in patients with HIV infection. Studies of biomarker associations with bacterial pneumonia risk in treated HIV-
infected patients do not currently exist.
Methods: We performed a nested, matched, case-control study among participants randomized to continuous combination
antiretroviral therapy (cART) in the Strategies for Management of Antiretroviral Therapy trial. Patients who developed
bacterial pneumonia (cases) and patients without bacterial pneumonia (controls) were matched 1:1 on clinical center,
smoking status, age, and baseline cART use. Baseline levels of Club Cell Secretory Protein 16 (CC16), Surfactant Protein D
(SP-D), C-reactive protein (hsCRP), interleukin-6 (IL-6), and d-dimer were compared between cases and controls.
Results: Cases (n = 72) and controls (n = 72) were 25.7% female, 51.4% black, 65.3% current smokers, 9.7% diabetic, 36.1%
co-infected with Hepatitis B/C, and 75.0% were on cART at baseline. Median (IQR) age was 45 (41, 51) years with CD4+ count
of 553 (436, 690) cells/mm3. Baseline CC16 and SP-D were similar between cases and controls, but hsCRP was significantly
higher in cases than controls (2.94 mg/mL in cases vs. 1.93 mg/mL in controls; p = 0.02). IL-6 and d-dimer levels were also
higher in cases compared to controls, though differences were not statistically significant (p-value 0.06 and 0.10,
respectively).
Conclusions: In patients with cART-treated HIV infection, higher levels of systemic inflammatory markers were associated
with increased bacterial pneumonia risk, while two pulmonary-specific inflammatory biomarkers, CC16 and SP-D, were not
associated with bacterial pneumonia risk.
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Introduction
Globally in 2010, approximately 34 million persons were living
with human immunodeficiency virus (HIV) infection and an
estimated 1.8 million people died of acquired immunodeficiency
syndrome (AIDS) [1]. Effective combination antiretroviral therapy
(cART) has greatly improved life expectancy and decreased the
incidence of Pneumocystis pneumonia [2] and bacterial pneumo-
nia [3]. However, community-acquired bacterial pneumonia
continues to present as a major clinical problem.
Highlighting the scale of problem is the observation made in the
Strategies for Management of Antiretroviral Therapy (SMART)
trial [4], where 65% of the adverse clinical events were non-AIDS
related and single episodes of bacterial pneumonia were the most
frequent clinical event at 2.1% (during a mean follow-up time of
16 months) [5]. A cohort study of US women reported the rate of
bacterial pneumonia at 8.5 per 100 person-years in HIV-infected
patients, a 12-fold increase compared to a rate of 0.7 per 100
person-years in HIV-uninfected patients [6]. Importantly, bacte-
rial pneumonia in that study was also associated with faster time to
death, even after adjustment for CD4+ count and cART use. A
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Danish cohort study also reported that hospitalization for bacterial
pneumonia was associated with an increased risk of death, even
more than one year after the hospitalization [3]. Bacterial
pneumonia in HIV-infected patients is also associated with
permanent declines in lung function [7], more airflow obstruction
[8], and a higher risk of lung cancer [9].
Major risk factors for bacterial pneumonia in patients with HIV
infection include lower CD4+ count, higher viral load, older age,
cigarette smoking, lack of cART, interruption of cART, alcohol
use, injection drug use, and lack of pneumococcal vaccination
[5,6,10–14]. Despite the significant impact of bacterial pneumonia
in HIV-infected patients, there are currently no additional tools to
predict bacterial pneumonia risk in HIV infection. In addition, the
mechanisms by which HIV increases bacterial pneumonia risk,
once effective treatment with cART is started, are unknown.
Patients with HIV infection demonstrate abnormal chronic
pulmonary inflammatory responses such as a CD8+ T-cell
alveolitis in bronchoalveolar lavage fluid [15]. We hypothesized
that this abnormal pulmonary inflammation may play a role in the
higher bacterial pneumonia risk observed in patients with HIV
infection. We further hypothesized that such relationships would
be independent of the systemic inflammation often observed in
patients with HIV infection [16]. We therefore examined
relationships between biomarkers, both lung-specific and non-
organ-specific, and bacterial pneumonia events among a cohort of
patients with treated HIV infection.
Methods
Study Population
We performed a nested, matched case-control study, using
previously collected data and stored blood samples from the
SMART trial (ClinicalTrials.gov identifier NCT00027352) [4].
The SMART trial established the superiority of a strategy of
continuous cART compared to intermittent cART.
Eligibility criteria for the SMART trial included a CD4+ count
greater than 350 CD4+ cells/mm3, and an age greater than 13
years. Within the SMART cohort, 204 participants experienced a
bacterial pneumonia event–82 in the continuous cART arm and
122 in the intermittent cART arm. We examined the current
clinically relevant question of whether biomarkers could help
determine bacterial pneumonia risk in the continuous cART arm,
which represents the current standard of providing continuous
cART once cART is started. Therefore, cases were defined as
patients who developed bacterial pneumonia in the continuous
cART arm of SMART. Controls were selected among SMART
participants in the continuous cART arm who did not develop
bacterial pneumonia (case:control ratio of 1:1) matched on clinical
center, smoking status, age 610 years, and baseline cART use.
The SMART trial was approved by each study center’s local
institutional review board and/or ethics committee, all patients
provided written informed consent using procedures approved by
local institutional review boards and/or ethics committees, and
documentation of informed consent was confirmed by the central
statistical and data management center prior to study enrollment.
Participants in this secondary analysis also provided written
informed consent for storage and future analysis of their biologic
specimens for analyses such as this current study (see acknowl-
edgement section for a complete list of study centers from which
participants in this secondary analysis were selected). Written
informed consent was obtained from next of kin, caretakers, or
legal guardians on the behalf of the minors and children in the
trial.
Data Collection and Follow-up
Before randomization, participants received a targeted physical
examination and had their medical history taken. Baseline data
included history of smoking (current, past, or never) and injection-
drug use. Participants were asked at baseline about their history of
prior AIDS-defining events, including history of prior/recurrent
bacterial pneumonia. No information was collected about
immunizations or about the routine use of antibiotics, including
co-trimoxazole as opportunistic infection prophylaxis. Follow-up
study visits were scheduled at 1 and 2 months after randomization,
then every 2 months for the first year, and then every 4 months for
the remainder of the study.
During the study, a standardized case report form was used to
collect information on patients with suspected bacterial pneumo-
nia. Patients were evaluated for pneumonia using local clinical
standards and guidelines. A central clinical events committee,
blinded to study arm, evaluated each report and classified bacterial
pneumonia events into one of three categories: (1) ‘‘confirmed’’
(compatible clinical and radiographic evidence with histologic or
microbiologic support); (2) ‘‘probable’’ (signs and symptoms of
pneumonia with compatible radiographic abnormalities); or (3)
‘‘suspected’’ (signs or symptoms of pneumonia with no supporting
radiographic evidence). In this report, we include data on patients
with bacterial pneumonia that was classified by the clinical
endpoint committee as ‘‘confirmed’’ or ‘‘probable.’’
Biomarker Measurements
In order to test our hypothesis regarding the relationship of
baseline blood biomarkers of inflammation and subsequent
bacterial pneumonia events, we chose to evaluate five biomarkers,
two of which are felt to be specific for pulmonary inflammation–
Club (Clara) cell protein 16 (CC16) and surfactant protein D (SP-
D)–and three non-organ-specific markers of systemic inflamma-
tion–high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-
6), and d-dimer.
Baseline serum samples prior to randomization were collected at
SMART sites, centrifuged locally, then shipped to and stored at
270C at the study biospecimen repository (Advanced BioMedical
Laboratories, Cinnaminson, NJ, USA). CC16 and SP-D levels
were analyzed using commercially available sandwich ELISA kits
(RD191022200 and RD194059101, BioVendor, Candler, NC,
USA). hsCRP was measured using nephelometry (N High
Sensitivity CRP; Siemens Healthcare Diagnostics, Deerfield, IL).
IL-6 was measured by ultra-sensitive ELISA (Quantikine HS
Human IL-6 Immunoassay; R&D Systems, Minneapolis, MN). D-
dimer was measured by immunoturbidimetry (STA Liatest D-Di,
STA-R analyzer, Diagnostica Stago, Asnie`res, France).
Statistical Analyses
Baseline characteristics and biomarker levels were compared
between cases and controls using conditional logistic regression
models, accounting for the matching covariates of age, smoking,
cART use and site of enrollment. An additional conditional
logistic regression model included additional covariates of gender,
race, HIV RNA, CD4+ count, prior AIDS, IV drug use and lipid-
lowering drug use. Univariate logistic regression was used to
compare biomarkers between smokers and non-smokers. In order
to assess the ability of biomarkers to discriminate between case
versus control status of a study participant, we also report the C-
statistic (area under the receiver-operating characteristic [ROC]
curve) for unconditional logistic regression models. All analyses
were two-sided.
Biomarkers and Bacterial Pneumonia Risk in HIV
PLOS ONE | www.plosone.org 2 February 2013 | Volume 8 | Issue 2 | e56249
Results
Among the 82 cases with bacterial pneumonia, 72 had stored
blood available for this analysis. Most pneumonia cases had no
organisms identified, but of the documented organisms, there were
6 cases of Streptococcus pneumoniae, 4 cases of Legionella pneumophilia,
and 1 case each of Group B Streptococcus, Staphylococcus aureus,
Haemophilus influenzae, and Acinetobacter baumanii. The median time
from baseline study entry to pneumonia event was 17 months
(IQR: 9–33 months). We were able to appropriately match all 72
cases to controls for a total sample size of 144 patients. Baseline
demographic data for cases and controls are presented in Table 1.
The two groups were similar with respect to baseline character-
istics except for the bacterial pneumonia cases having a borderline
higher proportion with prior AIDS (p= 0.06), lower proportion of
lipid-lowering medication use (p = 0.06), and lower mean LDL
level (p = 0.08).
Comparison of biomarker levels between smokers (n = 94) and
non-smokers (n = 50) (Table 2) showed that smokers had
significantly lower CC16 levels than non-smokers, consistent with
previous reports [17,18]. SP-D, hsCRP, IL-6, and d-dimer levels
were not statistically significantly different between smokers and
non-smokers, although we had limited power for such compari-
sons. Among the 144 pooled cases and controls, there were no
strong correlations between the five measured baseline biomark-
ers, with the exception of a modest correlation between hsCRP
and IL-6 (r = 0.49, p,0.001) and d-dimer and IL-6 (r = 0.52,
p,0.001)(Table 3).
For the primary analysis comparing baseline biomarker levels
between cases and controls there was no statistical difference in
SP-D or CC16 levels (Table 4). However, baseline hsCRP was
significantly higher in cases than controls (2.94 mg/mL in cases vs.
1.93 mg/mL in controls; p = 0.02). IL-6 and d-dimer levels were
also higher in cases compared to controls, although these
comparisons did not meet statistical significance criteria (unad-
justed p-values of 0.06 and 0.10, respectively). Adjusting for
additional covariates did not alter these findings (Table 4).
ROC analyses of biomarker levels to discriminate the case
versus control status of a given study participant showed that
baseline covariates had a ROC area under curve (C-statistic) of
0.63 (Table 5). The addition of biomarker levels, alone or in
combination, did not significantly improve the ability of the model
to discriminate between the case versus control status of a given
study participant.
During our study, hsCRP, IL-6 and d-dimer levels were
measured at baseline for all SMART participants. Therefore,
while data were available only for a 1:1 case:control ratio to study
CC16 and SP-D, we were able to expand the number of controls
for the hsCRP, IL-6, and d-dimer analyses. This was an
unplanned post-hoc analysis. The resulting case:control mix of
72 cases and 238 controls resulted in similar odds ratios to our
initial case:control ratio, but the added power resulted in lower p-
values for hsCRP (OR 1.8; 95% CI:1.2–2.7; p = 0.006), IL-6 (OR
Table 1. Baseline characteristics for SMART trial participants with a bacterial pneumonia event (cases) and controls matched on
age, smoking status, baseline antiretroviral therapy use, and clinical center.
Cases (n=72) Matched Controls (n=72) p-value1
Age, median years (IQR) 45 (41, 50) 45 (41, 52) –
Gender (% female) 25.0 26.4 0.86
Race (% black) 51.4 51.4 0.99
Nadir CD4+ count, median cells/mm3 (IQR) 230 (124, 365) 257 (172, 353) 0.22
CD4+ count, median cells/mm3 (IQR) 519 (447, 635) 613 (436, 723) 0.30
HIV RNA #400 copies/mL (%) 52.8 55.6 0.68
Prior AIDS (%) 43.1 27.8 0.06
On antiretroviral therapy (%) 75.0 75.0 –
Antiretroviral therapy naive (%) 1.4 5.6 0.22
Co-infection with hepatitis B or C (%) 36.1 36.1 0.99
History of IDU (%) 18.1 16.7 0.81
Current smoker (%) 65.3 65.3 –
Diabetes (%) 8.3 11.1 0.59
Blood pressure lowering drugs (%) 29.2 23.6 0.42
Lipid lowering drugs (%) 6.9 18.1 0.06
Prior cardiovascular disease (%) 4.2 5.6 0.71
BMI, median kg/m2 (IQR) 25.6 (21.5, 29.7) 26.6 (22.9, 29.9) 0.24
Total cholesterol, median mg/dl (IQR) 169 (146, 207) 183 (158, 213) 0.10
HDL cholesterol, median mg/dl (IQR) 38 (33, 49) 42 (31, 54) 0.65
LDL cholesterol, median mg/dl (IQR) 94 (64, 123) 102 (81, 126) 0.08
Triglycerides, median mg/dl (IQR) 166 (97, 249) 159 (93, 299) 0.68
Total/HDL, median (IQR) 4.4 (3.2, 5.5) 4.6 (3.3, 6.2) 0.77
1p-value from univariate conditional logistic model.
AIDS = acquired immunodeficiency syndrome, BMI = body mass index, HDL =high density lipoprotein, HIV = human immunodeficiency virus, IQR = interquartile range,
IDU= injection drug use, LDL = low density lipoprotein, RNA= ribonucleic acid.
doi:10.1371/journal.pone.0056249.t001
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1.7; 95% CI:1.2–2.6; p = 0.005), and d-dimer (OR 1.5; 95%
CI:1.0–2.2; p = 0.07).
Discussion
We hypothesized that biomarkers of pulmonary inflammation
would predict the development of bacterial pneumonia better than
systemic markers of inflammation, but we found the opposite–
hsCRP and IL-6 were related to bacterial pneumonia, but not
CC16 or SP-D.
We studied CC16 and SP-D because they are proteins primarily
produced in the lungs. CC16 is a 16 kDa protein produced by the
non-ciliated club cells found in segmental bronchi, and CC16 is
thought to play an anti-inflammatory role within the airways [19].
SP-D is a trimeric protein composed of three 43 kDa monomers
and is secreted mainly by alveolar type II pneumocytes. In contrast
to other surfactants that reduce alveolar surface tension, SP-D is
believed to play an anti-inflammatory role at the alveolar level,
while also playing a role in innate immunity [20]. Both CC16 and
SP-D are secreted into the airways and alveoli where they exert
their main functions, but levels are detectable in blood and
become elevated in lung injury [21–23], supporting the potential
use of these as non-invasive biomarkers of inflammation, injury,
and epithelial integrity of the lung lining surfaces.
Our results suggest that baseline CC16 and SP-D have no
relationship to bacterial pneumonia risk, at least in patients with
HIV infection receiving effective cART. Among patients with
chronic obstructive pulmonary disease (COPD), high serum SP-D
levels are associated with an increased risk of acute exacerbations
of COPD [24], most of which are triggered by bacterial or viral
respiratory infections. However in this study, we were only able to
assess for adjudicated bacterial pneumonia events and not more
minor respiratory infections such as bronchitis episodes or viral
and atypical pulmonary infections. We also note that these
biomarkers may be susceptible to changes over time from a variety
of pulmonary irritants [25]. Because we had only a single CC16
and SP-D measurement, we could not necessarily establish their
stability, and this may have affected our results.
Our findings that baseline levels of the systemic inflammatory
biomarkers hsCRP, IL-6, and d-dimer were associated with
subsequent bacterial pneumonia risk are supported by previously
published data. Among 3,075 community-dwelling elderly partic-
ipants (mean age 73.6 years) followed for 6.5 years in the Health
Aging and Body Composition cohort, higher baseline IL-6 levels
were associated with a higher risk of developing subsequent
community-acquired pneumonia [26]. Higher levels of plasma
tumor necrosis factor, another marker of systemic inflammation,
were also associated with an increased risk of pneumonia. CRP
levels in that study were unrelated to pneumonia risk, though the
CRP assay used in that study was not a newer high-sensitivity
assay such as the one we used, so their CRP data may have been
compromised to some degree. Two other studies of patients
undergoing cardiac surgery also showed that elevated preoperative
CRP levels were associated with increased postoperative respira-
tory infection risk [27,28].
The mechanisms by which elevated systemic inflammatory
markers are associated with increased bacterial pneumonia risk are
not clear. Gram-negative bacteria express surface receptors for
cytokines and in-vitro data have shown that IL-6, interferon
gamma and other inflammatory cytokines promote bacterial
growth in concentration-dependent fashion [29,30], suggesting
that these inflammatory markers may play a direct role in
susceptibility to bacterial pneumonia. However, CRP has been
shown to activate complement pathways and lead to opsonization
of bacteria such as Streptococcus pneumonia [31], suggesting that CRP
should perhaps be protective against pneumonia. Alternatively,
systemic inflammatory markers may simply be markers of
susceptibility rather than direct mediators of bacterial pneumonia
risk. While we found no difference in co-morbid conditions
associated with increased systemic inflammation such as diabetes
or cardiovascular disease, we cannot exclude the possibility that
elevations in systemic inflammatory markers might reflect other
clinically unrecognized factors, such as lung disease, that render
the host susceptible to pneumonia.
Underlying lung disease was not assessed as part of the SMART
trial, so we could not compare nor adjust for conditions such as
COPD present at baseline. Given that: 1) systemic inflammation is
commonly observed in patients with COPD [32], 2) COPD is a
risk factor for bacterial pneumonia [33,34] and 3) HIV infection is
an independent risk factor for COPD [35], we cannot exclude the
possibility that the risk associated with elevated hsCRP, IL-6, and
Table 2. Median (IQR) levels of Surfactant Protein-D (SP-D), Club Cell Protein 16 (CC16), high-sensitivity C-reactive protein (hsCRP),
Interleukin-6 (IL-6), and d-dimer levels by baseline smoking status (cases and controls combined).
Smokers (n =94) Non-smokers (n =50) OR (95% CI)1 p-value2
CC16 (ng/mL) 4.1 (3.1, 6.4) 6.4 (4.6, 9.4) 0.5 (0.3–0.7) ,0.001
SP-D (ng/mL) 105 (69, 147) 87 (71, 120) 1.2 (0.8–1.9) 0.33
hsCRP (mg/mL) 2.37 (0.98, 5.43) 2.16 (1.12, 4.46) 1.2 (0.8, 1.8) 0.49
IL-6 (pg/mL) 2.36 (1.52, 4.40) 2.38 (1.32, 3.85) 1.1 (0.7, 1.7) 0.73
d-dimer (mg/mL) 0.30 (0.20, 0.59) 0.28 (0.17, 0.63) 0.9 (0.6, 1.4) 0.69
1OR for smokers vs. non-smokers associated with a 1 IQR higher marker level after loge transformation.
2p-values from univariate logistic model.
doi:10.1371/journal.pone.0056249.t002
Table 3. Spearman correlation coefficients (p-value) between
baseline Club Cell Protein 16 (CC16), Surfactant Protein-D (SP-
D), high-sensitivity C-reactive protein (hsCRP), Interleukin-6
(IL-6), and d-dimer for cases and controls combined.
CC16 hsCRP IL-6 d-dimer
SP-D 0.08 (0.37) 0.04 (0.66) 0.03 (0.71) 0.05 (0.59)
CC16 0.06 (0.50) 0.12 (0.15) 0.13 (0.13)
hsCRP 0.49 (,0.001) 0.16 (0.06)
IL-6 0.52 (,0.001)
doi:10.1371/journal.pone.0056249.t003
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d-dimer levels we observed might reflect underlying lung disease.
Recent data from HIV-infected patients demonstrates that ex-vivo
stimulation of monocyte Toll-Like Receptor 2 (TLR2) upregulates
inflammatory genes, including IL-6 pathways [36]. While gut
microbial translocation is often cited as an etiology for TLR2
activation in HIV-infected patients, underlying lung disease such
as COPD is also associated with TLR2 activation [37], possibly
due to airway colonization with non-typeable Haemophilus influenzae
[38].
We did note that prior AIDS was more common and lipid-
lowering therapy use was lower in the bacterial pneumonia cases,
compared to controls. Given that HMG-coA reductase inhibitors
(i.e. statins) decrease hsCRP in the general population [39] and in
patients with HIV infection [40,41] and given that statins have
been associated with possible decreased bacterial pneumonia risk
[42], we included lipid-lowering therapy in a multivariate model.
In this model, hsCRP continued to be higher in cases than
controls, suggesting that the relationship between hsCRP and
bacterial pneumonia is not simply due to hsCRP effects of statin
use. Similar adjustment for prior AIDS did not change results.
Our study has several important limitations including a
case:control design and limited sample size. While we matched
on known confounders such as age and smoking status, and we
adjusted for other potential confounders in our multivariate
analyses, our analyses could still have been affected by other
unrecognized confounders. While bacterial pneumonia was the
most common clinical event reported in the SMART trial, it was
still an infrequent event overall at 3.7% of participants over a
mean follow-up of 32 months. While a larger case:control ratio for
CC16 and SP-D would have increased the power for those
analyses, the odds ratio point estimates of 1.2 and 0.8, respectively,
suggest the lack of significant associations for these markers was
not due to low power.
A major strength of our study is the adjudication of bacterial
pneumonia events by a blinded endpoint review committee, rather
than relying on clinician-diagnosed bacterial pneumonia or
administrative data. As such, the cases were well defined. Our
study population of treated participants with moderate/high CD4
counts and at low risk for AIDS is also a strength, in that they
accurately represent contemporary patients in regions with access
to cART. Other strengths of the study include the multi-center
nature of the cohort and the close follow-up of patients as part of a
clinical trial. Finally, we must acknowledge that while baseline
levels of systemic inflammatory markers were higher in cases that
eventually developed pneumonia compared to controls, our ROC
analyses suggest that the use of these biomarkers in clinical
decision-making appears limited.
In conclusion, among patients with HIV infection treated with
continuous cART, patients with elevated baseline levels of
systemic markers of inflammation appear to be at higher risk of
developing bacterial pneumonia, and raises the question of
whether treatments directed at reduction of systemic inflammation
might reduce the risk of bacterial pneumonia. Two pulmonary-
specific markers of lung inflammation, CC16 and SP-D, had no
relationship to bacterial pneumonia. The mechanistic explanations
for these observed relationships require further investigation.
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